Outcomes in COVID-19 nigella sativa studies
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ashraf (RCT) 82%
0.18 [0.04-0.80]
death
2/157
11/156
CT1
Improvement, RR [CI] Treatment Control Al-Haidari (RCT) 96%
0.04 [0.00-0.70]
death
0/160
14/259
Koshak (RCT) 75%
0.25 [0.03-2.22]
hosp.
1/91
4/92
Tau2 = 0.00; I2 = 0.0%
Early treatment 84%
0.16 [0.05-0.48]
3/408
29/507
84% improvement Al-Haidari 62%
0.38 [0.31-0.46]
symp. case
68/188
180/188
Improvement, RR [CI] Treatment Control Tau2 = 0.00; I2 = 0.0%
Prophylaxis 62%
0.38 [0.31-0.46]
68/188
180/188
62% improvement All studies 67%
0.33 [0.21-0.52]
71/596
209/695
67% improvement 4 nigella sativa COVID-19 studies c19ns.com Dec 7, 2021
1 CT: study uses combined treatment Tau2 = 0.06; I2 = 10.1%; Z = 4.72 Effect extraction pre-specified
Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ashraf (RCT) 82%
0.18 [0.04-0.80]
2/157
11/156
CT1
Improvement, RR [CI] Treatment Control Al-Haidari (RCT) 96%
0.04 [0.00-0.70]
0/160
14/259
Tau2 = 0.00; I2 = 0.0%
Early treatment 87%
0.13 [0.04-0.49]
2/317
25/415
87% improvement All studies 87%
0.13 [0.04-0.49]
2/317
25/415
87% improvement 2 nigella sativa COVID-19 mortality results c19ns.com Dec 7, 2021
1 CT: study uses combined treatment Tau2 = 0.00; I2 = 0.0%; Z = 3.02 Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Koshak (RCT) 75%
0.25 [0.03-2.22]
hosp.
1/91
4/92
Improvement, RR [CI] Treatment Control Tau2 = 0.00; I2 = 0.0%
Early treatment 75%
0.25 [0.03-2.22]
1/91
4/92
75% improvement All studies 75%
0.25 [0.03-2.22]
1/91
4/92
75% improvement 1 nigella sativa COVID-19 hospitalization result c19ns.com Dec 7, 2021
Tau2 = 0.00; I2 = 0.0%; Z = 1.24
Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ashraf (RCT) 82%
0.18 [0.04-0.80]
death
2/157
11/156
CT1
Improvement, RR [CI] Treatment Control Al-Haidari (RCT) 96%
0.04 [0.00-0.70]
death
0/160
14/259
Koshak (RCT) 75%
0.25 [0.03-2.22]
hosp.
1/91
4/92
Tau2 = 0.00; I2 = 0.0%
Early treatment 84%
0.16 [0.05-0.48]
3/408
29/507
84% improvement All studies 84%
0.16 [0.05-0.48]
3/408
29/507
84% improvement 3 nigella sativa COVID-19 serious outcomes c19ns.com Dec 7, 2021
1 CT: study uses combined treatment Tau2 = 0.00; I2 = 0.0%; Z = 3.23 Effect extraction pre-specified
Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ashraf (RCT) 84%
0.16 [0.11-0.24]
no recov.
107 (n)
103 (n)
CT1
Improvement, RR [CI] Treatment Control Koshak (RCT) 43%
0.57 [0.42-0.78]
no recov.
34/91
60/92
Tau2 = 0.76; I2 = 96.2%
Early treatment 69%
0.31 [0.09-1.05]
34/198
60/195
69% improvement All studies 69%
0.31 [0.09-1.05]
34/198
60/195
69% improvement 2 nigella sativa COVID-19 recovery results c19ns.com Dec 7, 2021
1 CT: study uses combined treatment Tau2 = 0.76; I2 = 96.2%; Z = 1.88 Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ashraf (RCT) 82%
0.18 [0.12-0.27]
viral+
107 (n)
103 (n)
CT1
Improvement, RR [CI] Treatment Control Tau2 = 0.00; I2 = 0.0%
Early treatment 82%
0.18 [0.12-0.27]
0/107
0/103
82% improvement All studies 82%
0.18 [0.12-0.27]
0/107
0/103
82% improvement 1 nigella sativa COVID-19 viral clearance result c19ns.com Dec 7, 2021
1 CT: study uses combined treatment Tau2 = 0.00; I2 = 0.0%; Z = 8.68 Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ashraf (RCT) 82%
0.18 [0.04-0.80]
death
2/157
11/156
CT1
Improvement, RR [CI] Treatment Control Al-Haidari (RCT) 96%
0.04 [0.00-0.70]
death
0/160
14/259
Koshak (RCT) 75%
0.25 [0.03-2.22]
hosp.
1/91
4/92
Tau2 = 0.00; I2 = 0.0%
Early treatment 84%
0.16 [0.05-0.48]
3/408
29/507
84% improvement All studies 84%
0.16 [0.05-0.48]
3/408
29/507
84% improvement 3 nigella sativa COVID-19 Randomized Controlled Trials c19ns.com Dec 7, 2021
1 CT: study uses combined treatment Tau2 = 0.00; I2 = 0.0%; Z = 3.23 Effect extraction pre-specified
Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ashraf (RCT) 82%
0.18 [0.04-0.80]
2/157
11/156
CT1
Improvement, RR [CI] Treatment Control Al-Haidari (RCT) 96%
0.04 [0.00-0.70]
0/160
14/259
Tau2 = 0.00; I2 = 0.0%
Early treatment 87%
0.13 [0.04-0.49]
2/317
25/415
87% improvement All studies 87%
0.13 [0.04-0.49]
2/317
25/415
87% improvement 2 nigella sativa COVID-19 RCT mortality results c19ns.com Dec 7, 2021
1 CT: study uses combined treatment Tau2 = 0.00; I2 = 0.0%; Z = 3.02 Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Al-Haidari (RCT) 96%
0.04 [0.00-0.70]
death
0/160
14/259
Improvement, RR [CI] Treatment Control Koshak (RCT) 75%
0.25 [0.03-2.22]
hosp.
1/91
4/92
Tau2 = 0.00; I2 = 0.0%
Early treatment 87%
0.13 [0.02-0.72]
1/251
18/351
87% improvement Al-Haidari 62%
0.38 [0.31-0.46]
symp. case
68/188
180/188
Improvement, RR [CI] Treatment Control Tau2 = 0.00; I2 = 0.0%
Prophylaxis 62%
0.38 [0.31-0.46]
68/188
180/188
62% improvement All studies 69%
0.31 [0.15-0.67]
69/439
198/539
69% improvement 3 nigella sativa COVID-19 peer reviewed trials c19ns.com Dec 7, 2021
Tau2 = 0.17; I2 = 18.1%; Z = 3.01
Effect extraction pre-specified
Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ashraf (RCT) 82%
0.18 [0.04-0.80]
death
2/157
11/156
CT1
Improvement, RR [CI] Treatment Control Ashraf (RCT) 67%
0.33 [0.01-7.99]
death
0/107
1/103
CT1
Ashraf (RCT) 79%
0.21 [0.05-0.92]
death
2/50
10/53
CT1
Ashraf (RCT) 84%
0.16 [0.11-0.24]
no recov.
107 (n)
103 (n)
CT1
Ashraf (RCT) 75%
0.25 [0.15-0.41]
no recov.
50 (n)
53 (n)
CT1
Ashraf (RCT) 82%
0.18 [0.12-0.27]
viral+
107 (n)
103 (n)
CT1
Ashraf (RCT) 77%
0.23 [0.14-0.38]
viral+
50 (n)
53 (n)
CT1
Al-Haidari (RCT) 96%
0.04 [0.00-0.70]
death
0/160
14/259
Al-Haidari (RCT) 93%
0.07 [0.02-0.30]
severe case
2/160
44/259
Koshak (RCT) 75%
0.25 [0.03-2.22]
hosp.
1/91
4/92
Koshak (RCT) 43%
0.57 [0.42-0.78]
no recov.
34/91
60/92
Al-Haidari 62%
0.38 [0.31-0.46]
symp. case
68/188
180/188
nigella sativa COVID-19 outcomes c19ns.com Dec 7, 2021
Favors nigella sativa
Favors control
Please send us corrections, updates, or comments.
Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC .
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
